Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

NCT00684294 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
46
Enrollment
OTHER
Sponsor class

Stopped Since no safety issues have been reported to date in association with TAG vaccine, no further survival follow-up will be done.

Conditions

Interventions

Sponsor

Mary Crowley Medical Research Center